Top Biotech Stocks To Watch For 2019

Investment bank analysts are convinced these three biotech stocks are worth a lot more than their current market values. All have recently been given price targets that suggest they could double your money, or better.

Here’s why analysts are willing to stick their necks out and predict huge gains ahead for these fledgling drugmakers. Just remember, huge potential rewards usually come with a great deal of risk.

Company (Symbol) Bank Recent Price Target Implied Upside at Recent Prices
Tocagen Inc. (NASDAQ:TOCA) Citigroup $27 141%
Vital Therapies, Inc. (NASDAQ:VTL) Cantor Fitzgerald $18 142%
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Citigroup $8.50

156%

Data source: Analyst notes, Yahoo! Finance.

Tocagen: Brain cancer hopeful

Senator John McCain’s recent passing has drawn attention to a disease badly in need of new treatment options: brain cancer. Tocagen has an experimental gene therapy aimed at this underserved group, and success could send the stock screaming higher. 

Top Biotech Stocks To Watch For 2019: XO Group, Inc.(XOXO)

Advisors’ Opinion:

  • [By Joseph Griffin]

    SinglePoint (OTCMKTS:SING) and XO Group (NYSE:XOXO) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on XO Group, Inc. Common Stock (XOXO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    SinglePoint, Inc. Common Stock (NYSE: XOXO) and XO Group, Inc. Common Stock (NYSE:XOXO) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

  • [By Steve Symington]

    Shares of XO Group Inc. (NYSE:XOXO) were up 26% as of 3:00 p.m. EDT Tuesday after the parent company of The Knot agreed to merge with WeddingWire, Inc. in a deal valued at $933 million. 

  • [By Max Byerly]

    ValuEngine upgraded shares of XO Group (NYSE:XOXO) from a buy rating to a strong-buy rating in a research report sent to investors on Wednesday morning.

Top Biotech Stocks To Watch For 2019: CyberArk Software Ltd.(CYBR)

Advisors’ Opinion:

  • [By Chris Lange]

    Short interest at CyberArk Software Ltd. (NASDAQ: CYBR) increased to 473,000 shares from the previous level of 372,000. Shares were trading at $73.00, within a 52-week range of $40.62 to $78.36.

  • [By Chris Lange]

    Short interest at CyberArk Software Ltd. (NASDAQ: CYBR) decreased to 372,000 shares from the previous level of 377,000. Shares were trading at $77.38, within a 52-week range of $40.62 to $78.36.

  • [By Chris Lange]

    Short interest at CyberArk Software Ltd. (NASDAQ: CYBR) decreased to 465,800 shares from the previous level of 975,000. Shares were trading at $69.89, within a 52-week range of $39.34 to $71.25.

Top Biotech Stocks To Watch For 2019: Research Frontiers Incorporated(REFR)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Research Frontiers, Inc. (NASDAQ:REFR) insider Kevin Douglas acquired 163,044 shares of the stock in a transaction on Tuesday, September 11th. The shares were purchased at an average cost of $0.92 per share, with a total value of $150,000.48. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Shane Hupp]

    News articles about Research Frontiers (NASDAQ:REFR) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Research Frontiers earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media stories about the technology company an impact score of 46.129953752672 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

  • [By Ethan Ryder]

    Research Frontiers (NASDAQ: REFR) and RPX (NASDAQ:RPXC) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Leave a Reply

Your email address will not be published. Required fields are marked *